Inflation Skyrockets By 300% In 2021
Right now, we're seeing the highest inflation rates since 2008. The White House is printing trillions of dollars, devaluing your dollar, and raising prices for everyone.
A Surprising Way To Shield Wealth From Inflation
Jong Joseph Kim, insider at Inovio Pharmaceuticals

Jong Joseph Kim Insider Information

Dr. Jong Kim currently serves as the president, CEO and a director of Inovio Pharmaceuticals. 

Inovio is a pharmaceutical company that develops treatments for cancer and other chronic infectious diseases. The company, which spun out of the University of Pennsylvania Medical School and was known as VGX Pharmaceuticals until 2009, currently has around 300 employees and a market cap of $500 million. 

Dr. Kim co-founded VGX in 2000 and served as its president and CEO until the time of its acquisition by Inovio in 2009, during which time he assumed the roles of president, CEO and director. In his current role, he is working to develop vaccines for developed markets and developing-world markets to combat the world’s top infectious diseases. 

Prior to his career at VGX and Inovio, Dr. Kim spent eight years with Merck & Company Inc. There he led efforts to manufacture and develop a variety of FDA-approved products and developmental therapeutics, including FDA-approved vaccines for hepatitis and developmental vaccines and therapies for HIV AIDS. 

Drawing on his background as an immunologist, Dr. Kim has worked to publish over 100 peer-reviewed scientific papers, holds several patents, and sits on the editorial boards of various scientific review panels. He has been recognized for his contributions to the scientific community by various institutions, with recognition as one of the world’s Top 100 Young Innovators by Technology Review Magazine in 2002, one of the Philadelphia Business Journal’s 40 under 40, and as Ernst & Young’s Entrepreneur of the Year for Greater Philadelphia in 2015. 

Dr. Kim currently sits on the boards of the Council of Korean Americans and the International Vaccine Institute. He is also part of the inaugural class of the Health Innovators Fellowship at the Aspen Institute. As a native of South Korea, he has worked with the World Economic Forum and the Global Agenda Council on Korea to develop new vaccines to protect the world’s poorest populations. 

Dr. Kim holds a Ph.D. in biochemical engineering from the University of Pennsylvania and an M.B.A. in finance from the Wharton School. He received his undergraduate degree from MIT. 

What is Jong Joseph Kim's net worth?

The estimated net worth of Jong Joseph Kim is at least $9.28 million as of February 1st, 2021. Dr. Kim owns 1,078,313 shares of Inovio Pharmaceuticals stock worth more than $9,284,275 as of August 3rd. This net worth estimate does not reflect any other assets that Dr. Kim may own.

How do I contact Jong Joseph Kim?

The corporate mailing address for Dr. Kim and other Inovio Pharmaceuticals executives is 660 W. GERMANTOWN PIKE SUITE 110., PLYMOUTH MEETING PA, 19462. Inovio Pharmaceuticals can also be reached via phone at 858-410-3134 and via email at [email protected]

Has Jong Joseph Kim been buying or selling shares of Inovio Pharmaceuticals?

Jong Joseph Kim has not been actively trading shares of Inovio Pharmaceuticals within the last three months. Most recently, Jong Joseph Kim sold 62,500 shares of the business's stock in a transaction on Wednesday, February 3rd. The shares were sold at an average price of $14.24, for a transaction totalling $890,000.00. Following the completion of the sale, the chief executive officer now directly owns 1,078,313 shares of the company's stock, valued at $15,355,177.12.

Who are Inovio Pharmaceuticals' active insiders?

Inovio Pharmaceuticals' insider roster includes Peter Kies (CFO), and Jong Kim (CEO).

Are insiders buying or selling shares of Inovio Pharmaceuticals?

In the last twelve months, insiders at the biopharmaceutical company sold shares 20 times. They sold a total of 458,338 shares worth mmore than $5,630,680.22. The most recent insider tranaction occured on June, 09th when Jacqueline Elizabeth Shea COO bought 38,535 shares worth more than $385,735.35. Insiders at Inovio Pharmaceuticals own 2.9 % of the company.

Information on this page was last updated on 6/9/2021.

Jong Joseph Kim Insider Trading History at Inovio Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/3/2021Sell62,500$14.24$890,000.001,078,313View SEC Filing Icon  
2/1/2021Sell100,000$15.00$1,500,000.001,078,313View SEC Filing Icon  
7/30/2020Sell100,000$21.13$2,113,000.001,188,313View SEC Filing Icon  
1/13/2020Buy22,500$3.11$69,975.001,100,707View SEC Filing Icon  
6/3/2019Sell2,129,553$2.36$5,025,745.081,911,055View SEC Filing Icon  
5/31/2019Sell500,000$2.44$1,220,000.001,911,055View SEC Filing Icon  
5/21/2019Sell100,000$3.31$331,000.002,411,055View SEC Filing Icon  
5/16/2019Sell136,768$3.50$478,688.002,511,055View SEC Filing Icon  
9/12/2018Sell49,060$5.37$263,452.202,357,554View SEC Filing Icon  
4/12/2018Sell103,750$5.14$533,275.002,395,557View SEC Filing Icon  
3/31/2017Sell147,180$6.54$962,557.202,164,887View SEC Filing Icon  
8/12/2014Buy250,000$9.06$2,265,000.00View SEC Filing Icon  
4/15/2014Buy25,000$2.25$56,250.005,965,809View SEC Filing Icon  
4/2/2013Buy90,000$0.50$45,000.00View SEC Filing Icon  
3/20/2013Buy60,000$0.53$31,800.00View SEC Filing Icon  
See Full Table

Jong Joseph Kim Buying and Selling Activity at Inovio Pharmaceuticals

This chart shows Jong Joseph Kim's buying and selling at Inovio Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Inovio Pharmaceuticals Company Overview

Inovio Pharmaceuticals logo
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon optimized plasmids that have ability to help break the immune system's tolerance of cancerous or infected cells and facilitate cross-strain protection against unmatched and matched pathogen variants. The company is involved in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); Lassa fever; Zika virus; and the COVID-19 virus (coronavirus). Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company also has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800, which is currently in Phase I clinical testing for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
Read More

Today's Range

Now: $8.61
Low: $8.44
High: $8.69

50 Day Range

MA: $8.49
Low: $7.04
High: $10.03

2 Week Range

Now: $8.61
Low: $5.81
High: $22.13

Volume

2,881,264 shs

Average Volume

10,237,721 shs

Market Capitalization

$1.80 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.64
Report: Smaller, Established Pot Stocks Key to Profits in 2021
Cannabis investors have been burned in the past by big name companies that saw their stock values skyrocket overnight, only to plummet back to earth when the challenge of turning a profit proved too difficult. Experts say key to making money with cannabis stocks is to invest in smaller companies with a track record of success.
Find Out Why This Seattle Company Be the #1 Stock